Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weekly carfilzomib combo shows promise for elderly myeloma patients

NCT ID NCT02302495

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how well the combination works at controlling the disease. The study is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carfilzomib
What this could lead to
If successful, this could provide a new treatment option for elderly patients with multiple myeloma, improving response rates while reducing side effects.
What could go wrong
This is a small, early-phase study (32 patients) focused on finding the right dose and initial effectiveness. The combination may still cause significant side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

32 people

The number who actually took part.

Started

Jan 2014

Finished

Jul 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * able to understand and voluntarily sign an informed consent form * able to adhere to the study visit schedule and other protocol requirements. * age ≥ 65 years. * life expectancy \> 6 months.Patients must have Symptomatic Measurable previously Untreated MM * have measurable disease as defined by the following: quantifiable monoclonal M-component value in the serum and/or urine * eastern Cooperative Oncology Group performance status score ≤2 * dequate bone marrow function, documented within 72 hours and without transfusion 5 days prior to the first intake of investigational product no growth factor support Adequate organ function * subjects affiliated with an appropriate social security system. * male subjects must:Understand the potential teratogenic,and genotoxic risk of Melphalan if engaged in sexual activity with a pregnant female or a female of childbearing potential. * understand the potential genotoxic risk of Carfilzomib if engaged in sexual activity with a pregnant female or a female of childbearing potential. * practice complete abstinence or understand the need and agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential throughout the entire duration of study treatment, during dose interruptions and until at least 3 months after the end of treatment discontinuation of CMP, even if he has undergone a successful vasectomy. * if pregnancy or a positive pregnancy test does occur in the partner of a male study patient during study participation, the investigator must be notified immediately. * agree not to donate semen or sperm during study drug therapy and until at least 3 months after the end of treatment discontinuation of CMP. Exclusion Criteria: * any other uncontrolled medical condition or comorbidity that might interfere with subject's participation. * known positive for HIV or active infectious hepatitis, type B or C. * patient with terminal renal failure that require dialysis and clearance creatinine \< 30 ml/min. * prior history of malignancies, other than multiple myeloma, unless the patients has been free of the disease for ≥ 5 years. * prior local irradiation within two weeks before first dose * evidence of central nervous system (CNS) involvement. * unable to take corticotherapy at study entry * any ongoing adverse event or medical history \> grade 2 severity * persons protected by a legal regime (guardianship, trusteeship).Alkeran's (Melphalan) contraindication: Hypersensitivity to Melphalan or to any other constituents. * patients with heart failure class 3 and 4 according to the NYHA criteria, or patients with past history of myocardial infarction within the last 6 months or no controlled cardiac conduction abnormalities. * patients with a left ventricular ejection fraction under or equal to 45 % (LVEF ≤ 45%)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • CH Francilien

    Corbeil-Essonnes, 91106, France

  • CH Louis Pasteur

    Colmar, 68024, France

  • CH Meaux

    Meaux, 77104, France

  • CHRU, Hôpitaux de Brabois

    Vandœuvre-lès-Nancy, 54511, France

  • CHRU, Hôtel Dieu

    Nantes, 44035, France

  • CHU Henri Mondor

    Créteil, 94010, France

  • CHU Nimes CAREMEAU

    Nîmes, 30029, France

  • CHU de Limoges

    Limoges, 87000, France

  • Centre Hospitalier H. Duffaut

    Avignon, 84902, France

  • Centre Hospitalier Lyon Sud -1

    Pierre-Bénite, 69495, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, 71100, France

  • Centre Hospitalier de Chambery

    Chambéry, 73011, France

  • Centre Hospitalier de la côte basque

    Bayonne, 64109, France

  • Centre Jean Bernard

    Le Mans, 72000, France

  • Centre de NICE 2/ Hôpital Archet

    Nice, 06202, France

  • Centre hospitalier départemental La Roche sur Yon

    La Roche-sur-Yon, 85025, France

  • Chru Lille

    Lille, 59037, France

  • Groupe hospitalier Pitié Salpétrière

    Paris, 75651, France

  • Hopital J Monod

    Montivilliers, 76290, France

  • Hématologie Clinique, CHU, Hôpital d'Enfants

    Dijon, 21000, France

  • Hématologie Clinique, Hôpital Robert Debré, CHU Reims

    Reims, 51092, France

  • Hématologie, IUCT oncopole

    Toulouse, 31059, France

  • Hématologie, Institut Paoli Calmette

    Marseille, 13273, France

  • Hôpital E Muller

    Mulhouse, 68100, France

  • Hôpital Haut-Leveque

    Pessac, 33604, France

  • Hôpital Jean Minjoz

    Besançon, 25030, France

  • Hôpital Notre Dame de Bon Secours

    Metz, 57038, France

  • Hôpital St Antoine

    Paris, 75571, France

  • Hôpital St Antoine Béclére

    Clamart, 92140, France

  • Hôpital St Vincent de Paul - GH-ICL

    Lille, 59020, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, 33300, France

  • Unité de Recherche Clinique - CH Perigueux

    Périgueux, 24019, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.